Nurix Therapeutics, Inc. (NRIX) Form 10-Q — Oct 13, 2026
Nurix Therapeutics reported a $549.8 million net income ($4.93 basic EPS) for the three months ended August 31, 2026, versus an $86.4 million loss a year earlier, driven almost entirely by recognition of $653.2 million in license revenue from Roche's $700.0 million upfront payment for the bexobrutideg (NX-5948) collaboration that became effective in July 2026. The balance sheet was transformed: cash, cash equivalents and marketable securities reached roughly $1.1 billion as of August 31, 2026, up from about $593 million at fiscal year-end 2025, with no debt outstanding and $300.0 million still available under its at-the-market equity program.
Key figures
- Eps
- 4.93
- Revenue
- 673064000
- Net Income
- 549807000
- Total Debt
- 0
- Total Assets
- 1195298000
- Cash Position
- 720242000
- Shares Outstanding
- 109200394
- Accumulated deficit
- $630.1 million
- Roche upfront payment
- $700.0 million
- Zelebrudomide program
- discontinued August 2026
- Net income nine months
- $373.1 million vs $(186.2) million prior year
- Remaining atm capacity
- $300.0 million under Third Amended Equity Distribution Agreement
- Total revenue nine months
- $688.4 million vs $70.4 million prior year
- Cash plus marketable securities
- approximately $1.1 billion
- License revenue recognized q1 fy2026
- $653.2 million
- Collaborator nondilutive funding to date
- $1.2 billion
- Potential future milestones all partners
- up to $7.2 billion
- Gilead second research term extension fee
- $10.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.